Alpha-9 Theranostics, a Vancouver, B.C. and Boston-based biotech company developing radiotherapies, raised $75 million. The company was founded by researchers from the University of British Columbia and BC Cancer, and is led by David Hirsch, a venture partner at Longitude Capital, which led a previous $11 million Series A funding round. The company is building a research facility in Vancouver to advance development of its agents that selectively target radioisotopes to cancer cells. Nextech Invest led the Series B round, with participation from Longitude and other investors.
